NCT05372562

Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 30 (actual)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded.

Detailed description

Patients who were diagnosed as postoperative CME after uneventful intraocular surgery and administrated with intravitreal OZURDEX injection were reviewed. All patients underwent ophthalmic examinations at the initial visit and were followed up at months 1, 2, 3 and 6 with measurement of best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded. Risk factors of recurrent CME were analyzed

Conditions

• Macular Edema

Timeline

• Start date: 2017-07-01
• Primary completion: 2022-04-30
• Completion: 2022-04-30
• First posted: 2022-05-12
• Last updated: 2022-05-12

Locations

1 site across 1 country: China